Business
Cannabics Pharmaceuticals Collaborates With RCKMC to Develop Cannabis Strains Targeting Gastrointestinal Cancers
Cannabics Pharmaceuticals Collaborates With RCKMC to Develop Cannabis Strains Targeting Gastrointestinal Cancers.
About this update from Cnbx Pharmaceuticals Inc.
[{"type":"text","content":"\n\n\n\nCannabics Pharmaceuticals Collaborates With RCKMC to Develop Cannabis Strains Targeting Gastrointestinal Cancers\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nCannabics Pharmaceuticals Collaborates With RCKMC to Develop Cannabis Strains Targeting Gastrointestinal Cancers\nPR Newswire\nTEL AVIV, Israel and BETHESDA, Maryland, Feb. 11, 2020\n\n\n\nTEL AVIV, Israel and BETHESDA, Maryland, Feb. 11, 2020 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced today that it has signed a Memorandum Of Understanding with RCK Medical Cannabis to develop cannabis chemovars targeted to treat gastro intestinal cancers. \nRCKMC is an Israeli company, focused on breeding stable cannabis hybrid-seeds, tailor-made cannabis strains and genetic research, and a provider of a host of technologies, expertise and know-how throughout the entire medical cannabis grow cycle.\nCannabics and RCKMC plan to develop cannabis chemovars with cannabinoid profiles previously found to have antitumor properties in preclinical studies on Gastrointestinal cancers. These strains of the cannabis will be the source genetics for the development of botanically derived active pharmaceutical ingredients (API's).\nDr. Noam Chehanovsky, CTO and Co-Founder of RCKMC commented: \"We are intrigued to be involved in strain development designed to target cancer biopsies. We have a large variety of strains and nurturing expertise, which together with our proprietary breeding technologies, lead to a wide range of chemotypes to be examined by Cannabics.\"\nDr. Eyal Ballan, CTO and Co-Founder of Cannabics Pharmaceuticals said: \"RCKMC is a pioneer in the field of plant genetics and breeding. Its expertise will synergize with Cannabics' clinical capabilities to create the bases for proprietary drug development from seed to formulation.\" \nAbout RCKMC\nRCK is an Israeli cannabis company, breeding tailor-made medical strains and repeatable & stable cannabis hybrid-seeds, being the firs...